Berotralstat Treatment in Children With Hereditary Angioedema
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of berotralstat
to determine the appropriate weight-based dose for pediatric participants 2 to < 12 years old
for prophylactic treatment to prevent attacks of hereditary angioedema (HAE).